ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 77 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $188,240 | -77.2% | 31,114 | -70.8% | 0.00% | -50.0% |
Q2 2023 | $827,332 | +234.3% | 106,615 | +145.5% | 0.00% | +100.0% |
Q1 2023 | $247,494 | -9.8% | 43,420 | -6.8% | 0.00% | 0.0% |
Q4 2022 | $274,291 | -50.8% | 46,569 | -73.2% | 0.00% | -50.0% |
Q3 2022 | $557,000 | -47.2% | 174,065 | -26.0% | 0.00% | -33.3% |
Q2 2022 | $1,054,000 | -38.2% | 235,336 | -26.3% | 0.00% | -40.0% |
Q1 2022 | $1,705,000 | +214.6% | 319,355 | +942.2% | 0.01% | +400.0% |
Q2 2021 | $542,000 | – | 30,641 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |